BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/21/2025 10:13:03 AM | Browse: 35 | Download: 45
 |
Received |
|
2024-11-06 12:30 |
|
Peer-Review Started |
|
2024-11-06 12:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-12-24 03:32 |
|
Revised |
|
2025-01-05 20:35 |
|
Second Decision |
|
2025-01-13 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-14 13:12 |
|
Articles in Press |
|
2025-01-14 13:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-20 03:06 |
|
Publish the Manuscript Online |
|
2025-02-21 10:13 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Editorial |
| Article Title |
Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ileana Lulic, Dinka Lulic, Jadranka Pavicic Saric, Iva Bacak Kocman and Dunja Rogic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ileana Lulic, MD, Postdoctoral Fellow, Department of Anesthesiology, Intensive Care and Pain Medicine, Clinical Hospital Merkur, Zajceva 19, Zagreb 10000, Croatia. ileanalulic@gmail.com |
| Key Words |
Hepatocellular carcinoma recurrence; Liver transplantation; Personalized translational medicine; Biomarkers; YKL-40; Risk stratification |
| Core Tip |
YKL-40 aligns with the principles of personalized translational medicine by offering a biomarker-driven approach to patient care. Its ability to provide liver-specific insights enables tailored post-liver transplantation surveillance and risk stratification, addressing the unique recurrence risks of individual patients. By integrating YKL-40 into multi-biomarker panels and predictive models, clinicians can refine therapeutic strategies, monitor disease progression more effectively, and personalize interventions for high-risk individuals. This targeted approach not only enhances clinical outcomes but also supports the broader shift toward precision medicine in transplantation, ensuring that care is both patient-specific and evidence-driven. |
| Publish Date |
2025-02-21 10:13 |
| Citation |
<p>Lulic I, Lulic D, Pavicic Saric J, Bacak Kocman I, Rogic D. Personalized translational medicine: Investigating YKL-40 as early biomarker for clinical risk stratification in hepatocellular carcinoma recurrence post-liver transplantation. <i>World J Transplant</i> 2025; 15(2): 103036</p> |
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i2/103036.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i2.103036 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
